More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions

REFERENCES

1. 1.↵
   1. Alten R,
   2. Pohl C,
   3. Choy EH,
   4. Christensen R,
   5. Furst DE,
   6. Hewlett SE,
   7. et al.

   Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745–50.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Bingham CO 3rd,
   2. Alten R,
   3. Bartlett SJ,
   4. Bykerk VP,
   5. Brooks PM,
   6. Choy E,
   7. et al.

   Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Bingham CO 3rd,
   2. Pohl C,
   3. Woodworth TG,
   4. Hewlett SE,
   5. May JE,
   6. Rahman MU,
   7. et al.

   Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335–41.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Bykerk VP,
   2. Lie E,
   3. Bartlett SJ,
   4. Alten R,
   5. Boonen A,
   6. Christensen R,
   7. et al.

   Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol 2014;41:799–809.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Boers M,
   2. Kirwan JR,
   3. Wells G,
   4. Beaton D,
   5. Gossec L,
   6. d’Agostino MA,
   7. et al.

   Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Boers M,
   2. Kirwan JR,
   3. Gossec L,
   4. Conaghan PG,
   5. D’Agostino MA,
   6. Bingham CO 3rd,
   7. et al.

   How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol 2014;41:1025–30.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Kalyoncu U,
   2. Dougados M,
   3. Daurès JP,
   4. Gossec L

   . Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183–90.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Buttgereit F,
   2. Doering G,
   3. Schaeffler A,
   4. Witte S,
   5. Sierakowski S,
   6. Gromnica-Ihle E,
   7. et al.

   Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205–14.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Buttgereit F,
   2. Mehta D,
   3. Kirwan J,
   4. Szechinski J,
   5. Boers M,
   6. Alten RE,
   7. et al.

   Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013;72:204–10.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Buchbinder R,
    2. Bombardier C,
    3. Yeung M,
    4. Tugwell P

    . Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures’ responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995;38:1568–80.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Orbai AM,
    2. Smith KC,
    3. Bartlett SJ,
    4. De Leon E,
    5. Bingham CO 3rd.

    “Stiffness has different meanings, I think, to everyone”: examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res 2014;66:1662–72.

    OpenUrlCrossRef
12. 12.↵
    1. Halls S,
    2. Dures E,
    3. Kirwan J,
    4. Pollock J,
    5. Baker G,
    6. Edmunds A,
    7. et al.

    Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology 2014 Sep 16 (E-pub ahead of print).
13. 13.↵
    1. Patrick DL,
    2. Burke LB,
    3. Gwaltney CJ,
    4. Leidy NK,
    5. Martin ML,
    6. Molsen E,
    7. et al.

    Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument. Value Health 2011;14:967–77.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Patrick DL,
    2. Burke LB,
    3. Gwaltney CJ,
    4. Leidy NK,
    5. Martin ML,
    6. Molsen E,
    7. et al.

    Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health 2011;14:978–88.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Hewlett S,
    2. Sanderson T,
    3. May J,
    4. Alten R,
    5. Bingham CO 3rd,
    6. Cross M,
    7. et al.

    ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology 2012;51:69–76.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Bartlett SJ,
    2. Hewlett S,
    3. Bingham CO 3rd,
    4. Woodworth TG,
    5. Alten R,
    6. Pohl C,
    7. et al.

    Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855–60.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Flurey CA,
    2. Morris M,
    3. Richards P,
    4. Hughes R,
    5. Hewlett S

    . It’s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. Rheumatology 2014;53:696–703.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Sanderson TC,
    2. Hewlett SE,
    3. Flurey C,
    4. Dures E,
    5. Richards P,
    6. Kirwan JR

    . The impact triad (severity, importance, self-management) as a method of enhancing measurement of personal life impact of rheumatic diseases. J Rheumatol 2011;38:191–4.

    OpenUrlFREE Full Text